Molecular targets for potentiation of radiation-induced cell killing

Breast Cancer

Volumn 11, Issue 2, 2004, Pages 121-128

  Akimoto, Tetsuo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Molecular target; Molecular target based drug; Radiation; Radiosensitivity

Indexed keywords

RADIOSENSITIZING AGENT;

CELL DEATH; CLINICAL TRIAL; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION DOSE; REVIEW; TREATMENT OUTCOME;

CELL DEATH; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 16544382019     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968290     Document Type: Review

References (52)

1. Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998. (Pubitemid 28275077)
2. Ma B, Bristow RG, Kim J, Siu L: Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Onco121:2760-2776, 2003. (Pubitemid 46613486)
3. Hall EJ, Marchese M, Hei TK, Zaider M: Radiation response characteristics of human cells in vitro. Radiat Res 114:415-424, 1988.
4. Bristow RG, Benchimol S, Hill RP: The p53 gene as a modifier of intrinsic radiosensifivity: Implications for radiotherapy. Radiother Onco140:197-223, 1996. (Pubitemid 27314227)
5. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
6. Oda K, Arakawa H, Taya Y, et al: P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862, 2000.
7. Fei P, E1-Deiry: P53 and radiation response. Oncogene 22:5774-5783, 2003.
8. Lee JM, Bernstein A: P53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746, 1993. (Pubitemid 23176238)
9. Powell SN, Abraham EH: The biology of radioresistance: Similarities, differences and interactions with drug resistance. Cytotechnology 12:325-345, 1993.
10. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, E1-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9:93-101, 2003. (Pubitemid 36109720)
11. Brown JM: Therapeutic targets of radiotherapy. Int J Radiat Oncol Biol Phys 49:319-326, 2001.
12. Harari PM, Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289, 2001. (Pubitemid 32959663)
13. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogenactivated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493-2506, 1999. (Pubitemid 29393505)
14. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, Schmidt-Ullfich ILK: Ionizing radiation activates Erb-B receptor dependent Akt and p70 6 kinase signaling in carcinoma cells. Oncogene 21:4032-4041, 2002. (Pubitemid 34679244)
15. Hagan M, Wang L, Hanley JR, Park JS, Dent P: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiationinduced cell killing and G2/M-phase arrest. Radiat Res 153:371-383, 2000. (Pubitemid 30185389)
16. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S: MAPK pathways in radiation responses. Oncogene 22:5885-5896, 2003. (Pubitemid 37176709)
17. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KI Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884-2890, 1999. (Pubitemid 29493967)
18. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002. (Pubitemid 36025259)
19. Formenfi SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P: Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 52:397-405, 2002. (Pubitemid 34170845)
20. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L: Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758-1765, 2003. (Pubitemid 36350719)
21. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S: The role of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio-or chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenecity. Leukemia 12:1843-1850, 1998. (Pubitemid 28554457)
22. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakananskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ: Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892, 2002. (Pubitemid 34742122)
23. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW: Activation of Raf by ionizing radiation. Nature 382:813-816, 1996. (Pubitemid 26299565)
24. Gupta AK, Bernhard EJ, Bakanauskas VJ, Wu J, Muschel RJ, McKenna WG: RAS-Mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiat Res 154:64-72, 2000. (Pubitemid 30436510)
25. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353-360, 2003.
26. Pfeifer A, Mark G, Leung S, Dougherty M, Spillare E, Kasid U: Effects of c-raf-1 and c-myc expression on radiation response in an in vitro model of human smallcell-lung carcinoma. Biochem Biophys Res Commun 252:481-486, 1998. (Pubitemid 28542913)
27. Akimoto T, Mitsuhashi N, Saito Y, Ebara T, Niibe H: Effect of radiation on the expression of E-cadherin and alpha-catenin and invasive capacity in human lung cancer cell line in vitro. Int J Radiat Oncol Biol Phys 41:1171-1176, 1998. (Pubitemid 28377500)
28. Cordes N, Blaese MA, Meineke V, Van Beuningen D: Ionizing radiation induces up-regulation of functional betal-integrin in human lung tumour cell lines in vitro. Int J Radiat Bio178:347-357, 2002. (Pubitemid 34496887)
29. Masunaga S, Ono K, Akaboshi M, Takagaki M, Kinashi Y, Suzuki M, Abe M: Determination and drug modification assessed by micronucleus frequency assay of potentially lethal damage repair in quiescent cell populations within murine solid tumors. Radiat Meal 15:37-43, 1997. (Pubitemid 27166612)
30. Cordes N, van Beuningen D: Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. Br J Cancer 88:1470-1479, 2003. (Pubitemid 36606433)
31. Kraus AC, Ferber I, Bachmann SO, Specht H, Wimreel A, Gross MW, Schlegel J, Suske G, Schuermann M: In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21:8683-8695, 2002. (Pubitemid 36132389)
32. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ: Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914, 2003. (Pubitemid 37176711)
33. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P: Overexpression of hypoxia-inducible factor lalpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234-2240, 2003. (Pubitemid 36687648)
34. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000. (Pubitemid 30111496)
35. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999. (Pubitemid 29136268)
36. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528, 2000.
37. She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller V, Rusch VR, Kris MG, Sirotnak FM: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 9:3773-3778, 2003. (Pubitemid 37169247)
38. Nakagawa K, Yamamoto N, Kudoh S, et al: A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumors. Proc Am Soc Clin Oncol 19:183a, 2000 (abstr 711).
39. Akimoto T, Nonaka T, Harashima K, Ishikawa H, Sakurai H, Mitsuhashi N: Selective Inhibition of Survival Signal Transduction Pathways Enhanced Radiosensitivity in Human Esophageal Cancer Cell Lines In Vitro. AntiCancer Res (in press).
40. Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, Takahashi T, Mitsuhashi N: Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: Possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys 50:195-201, 2001.
41. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD: Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3:1149-1156, 1997. (Pubitemid 27319761)
42. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG: Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56:846-853, 2003. (Pubitemid 36677381)
43. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ: Farnesyltransferase inhibitors potentiate the anfitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125-132, 2000. (Pubitemid 30612910)
44. Pratt WB: The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 217:420-434, 1998.
45. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: A multitarget approach to radiosensitization. Clin Cancer Res 9:3749-3755, 2003. (Pubitemid 37169244)
46. Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419, 2001. (Pubitemid 32685816)
47. Kasahara T, Koguchi E, Funakoshi M, Aizu-Yokota E, Sonoda Y: Antiapoptotic action of focal adhesion kinase (FAK) against ionizing radiation. Antioxid Redox Signal 4:491-499, 2002. (Pubitemid 34753389)
48. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Onco119:3234-3243, 2001. (Pubitemid 32591441)
49. Hahn SM, Bernhard E J, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002. (Pubitemid 34517641)
50. National Cancer Institute: Clinical trials, http//www. cancer.gov/clinicaltrials.
51. Dicker AP, Anne P, Bonnani R, et al: Phase I trial results and preclinical studies of recombinant human Angiostafin and external beam radiation therapy. Proc Am Soc Clin Onco121:7a, 2002 (Abstr 23).
52. Soldatenkov VA, Dritschilo A, Wang FH, Olah Z, Anderson WB, Kasid U: Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. CancerJ SciAm 3:13-20, 1997.